• Preclinical models indicate roles for adiponectin in the mai

  2023-10-11

  

  Preclinical models indicate roles for adiponectin in the maintenance of hepatic lipid metabolism. Adiponectin overexpression prevents accumulation of triglycerides or the deleterious lipid metabolites diacylglycerols or ceramides [5,8]. Direct manipulation of adiponectin expression demonstrates a po

• ACK has been clearly implicated in cancer progression

  2023-10-11

  

  ACK1 has been clearly implicated in cancer progression in recent years. A strong correlation between ACK1 gene copy number, protein level and activity have been demonstrated in tumors of different tissue types (Mahajan et al., 2007; van der Horst et al., 2005; Wang et al., 2006). Our western blot an

• how to find the molarity of a solution The small fishers wit

  2023-10-10

  

  The small fishers with little or no quota who remained relied on quota leasing arrangements to continue their fishing operations. Such arrangements had relatively high transaction costs and by early 2000 it appeared that the demise of the small fisher was imminent [2]. The introduction in 2001 of t

• For the NSCLC patients with EGFR activating mutations

  2023-10-10

  

  For the NSCLC patients with EGFR-activating mutations, EGFR-TKIs (gefitinib and erlotinib) are effective clinical therapies [21], [22]. However, approximately 10% of patients harboring EGFR-sensitizing mutations exhibit intrinsic resistance, and up to 40% do not attain a major response to treatment

• Introduction Lipoxygenases LOXs are key enzymes that catalyz

  2023-10-10

  

  Introduction Lipoxygenases (LOXs) are key enzymes that catalyze the polyunsaturated fatty acids (PUFAs) such as arachidic Neuropeptide Y 13-36 (porcine) (AA), linoleic acid (LA) and others unsaturated fatty acids (Brash, 1999). LOXs are expressed in immune, neural, epithelial, tumor cells and other

• ATM is generally regarded to

  2023-10-10

  

  ATM is generally regarded to be the principal mediator of the G1 Boc-D-FMK checkpoint, whereas the induction of the intra-S-phase and G2/M checkpoints are usually primarily related to ATR function. However, several studies have demonstrated that, depending on the cellular context and type of DNA da

• The elevated levels of intracellular antioxidant such as red

  2023-10-10

  

  The elevated levels of intracellular antioxidant such as reduced glutathione (GSH) are normally oberserved is various tumor SQ 29,548 receptor which confers the chemoresistant to chemotherapy [59]. Therefore, the induction of oxidative stress via elevation of intracellular ROS and dimunition of int

• However one should keep in

  2023-10-10

  

  However, one should keep in mind that these results may not reflect exactly in vivo antioxidant activity. Many other issues such as absorption, metabolism and physicochemical properties of different antioxidants must also be considered (Prior et al., 2007, Wu et al., 2004). Some research groups are

• ghrelin receptor br Prostate cancer and resistance to AR tar

  2023-10-10

  

  Prostate cancer and resistance to AR targeting treatment The AR plays a pivotal role in the development, differentiation, homeostasis and secretory function of the normal prostate (Wilson, 2011). The AR is also a key player in many phases of prostate carcinogenesis (Huggins et al., 1941, Scher an

• The G R mutation is located

  2023-10-10

  

  The G1202R mutation is located at the solvent front of the ALK kinase domain adjacent to the inhibitor's binding pocket. Although barely reported in the setting of crizotinib resistance, it has emerged as the most refractory mutation to both the first- and second-generation ALK inhibitors. The large

• br Current therapies for metabolic diseases Inborn errors

  2023-10-10

  

  Current therapies for metabolic diseases Inborn errors of metabolism caused by deficiency of particular enzymes due to loss of function mutations or deletions have been treated by decreasing the intake of the enzymatic substrate, supplementation with an essential cofactor or vitamin, increasing m

• br Current therapies for metabolic diseases Inborn errors

  2023-10-10

  

  Current therapies for metabolic diseases Inborn errors of metabolism caused by deficiency of particular enzymes due to loss of function mutations or deletions have been treated by decreasing the intake of the enzymatic substrate, supplementation with an essential cofactor or vitamin, increasing m

• Increasing evidence indicates that ILCs participate in

  2023-10-10

  

  Increasing evidence indicates that ILCs participate in a dialog with CD4+ T Capsazepine australia [107–110]. This dialog is mediated, in part, through the expression of type II major histocompatibility complex (MHCII) molecules on ILC3s [107]. Depending on the expression of co-stimulatory molecules

• The disease stimulatory effects of hyperadiponectinemia

  2023-10-10

  

  The disease-stimulatory effects of hyperadiponectinemia in patients contradict a previous view based on studies of preclinical models showing that APN might be beneficial for AD [8]. Indeed, despite the action of APN as a risk factor in patients with AD, APN is protective against oxidative stress-in

• In order to improve the methodology of the synthesis of

  2023-10-09

  

  In order to improve the methodology of the synthesis of steroidal derivatives, our goal was the investigation of aza-Michael addition of different N-nucleophiles to 16-dehydropregnenolone in the presence of [DBU][OAc] as catalyst and reaction medium. Michael addition of electron deficient steroidal

15138 records 264/1010 page Previous Next First page 上5页 261262263264265 下5页 Last page